ERBB2 and ovarian carcinoma: Based on the absence of therapeutic options for HER2-overexpressing ovarian cancer, this study aimed to determine the anticancer efficacy of samfenet, a biosimilar compound of trastuzumab, combined with NK cells in preclinical models.